REGN


Are These 5 Biotech Stocks About to Get Bought Out?

In a previous article, I talked about the so-called patent cliff and the correlation to the pace of mergers and acquisitions in the pharma …

Dane Leone Fears Regeneron Pharmaceuticals Inc Could Be Facing Big Competition from Roche

After Roche released initially reassuring datasets for its wet AMD and DME candidate, BTIG’s Dane Leone believes this spells trouble for REGN.

Analysts Sidelined Despite Key Strides from Vertex Pharmaceuticals Incorporated (VRTX) and Regeneron Pharmaceuticals Inc (REGN)

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have excited investors with key clinical moves forward for the firms, between VRTX’s double …

Regeneron Pharmaceuticals Inc (REGN) and Sanofi (SNY) Win FDA Approval of DUPIXENT

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi (NYSE:SNY) announced that the FDA approved DUPIXENT® (dupilumab) Injection, the first and only biologic medicine approved for …

Company Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc and Sanofi to Appeal U.S. District Court Rulings in Ongoing Patent Litigation Regarding Praluent Injection

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi announced that they will appeal the injunction granted today by the U.S.

Company Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc Hires Dr. Jay Markowitz as Senior Vice President of Portfolio Management

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that Jay Markowitz, M.D.

Stock Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc Genetics Center and Geisinger Health System Receive Recognition in Science for Collaborative Precision Medical Approach

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Geisinger Health System (Geisinger) today announced that Science has published a paper describing how the DiscovEHR collaboration between …

Stock Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc and Sanofi Announce Marketing Authorization Application for Dupixent Accepted for Review by the EMA

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for …

The Biotech Corner: Valeant Pharmaceuticals Intl Inc (VRX), Regeneron Pharmaceuticals Inc (REGN), and Mylan NV (MYL)

The biotech world is buzzing after a criminal charge-laden press release has circled the name of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Regeneron Pharmaceuticals …

Stock Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc and Sanofi Announce Praluent Cardiovascular Outcomes Trial Will Continue as Planned Following Interim Analysis

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi announced that the ongoing Praluent® (alirocumab) ODYSSEY OUTCOMES trial will continue as planned, based on the recommendation of …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts